We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+21.69%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$274M
Cap. Flow
+$156M
Cap. Flow %
15.15%
Top 10 Hldgs %
40.17%
Holding
97
New
37
Increased
20
Reduced
20
Closed
12

Top Buys

1
HRTX icon
Heron Therapeutics
HRTX
+$29.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$24.7M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$22.5M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$20.5M
5
EBS icon
Emergent Biosolutions
EBS
+$18.5M

Top Sells

1
LCI
Lannett Company, Inc.
LCI
+$25.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.4M
3
ASRT
Assertio
ASRT
+$19.7M
4
NVDQ
Novadaq Technologies Inc.
NVDQ
+$14.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M

Sector Composition

1 Healthcare 79.95%
2 Technology 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCRA
76
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$2.62M 0.25%
+160,597
New +$2.71M
ANTH
77
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.57M 0.25%
95,791
– –
CUTR
78
DELISTED
Cutera, Inc.
CUTR
$2.42M 0.23%
215,962
– –
TLPH icon
79
Talphera
TLPH
$68.5M
$2.4M 0.23%
10,000
– –
NSPH
80
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$2.15M 0.21%
+50,000
New +$2.36M
AMRN
81
Amarin Corp
AMRN
$292M
$1.81M 0.18%
+50,000
New +$1.86M
CORV
82
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.58M 0.15%
+200,000
New +$1.61M
OPCH icon
83
Option Care Health
OPCH
$3.41B
$1.54M 0.15%
+55,000
New +$1.7M
STRR
84
DELISTED
Star Equity Holdings
STRR
$1.14M 0.11%
6,650
+2,160
+48% +$380K
CRDC
85
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$641K 0.06%
64,035
-413,232
-87% -$4.72M
ASMB icon
86
Assembly Biosciences
ASMB
$531M
– –
-30,831
Closed -$7.07M
GYRE icon
87
Gyre Therapeutics
GYRE
$675M
– –
-380
Closed -$1.24M
RAD
88
DELISTED
Rite Aid Corporation
RAD
– –
-25,000
Closed -$2.53M
ISEE
89
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-150,000
Closed -$4.85M
AERI
90
DELISTED
Aerie Pharmaceuticals
AERI
– –
-391,232
Closed -$7.03M
EPZM
91
DELISTED
Epizyme, Inc
EPZM
– –
-100,000
Closed -$2.08M
NXTM
92
DELISTED
NxStage Medical Inc.
NXTM
– –
-543,466
Closed -$5.43M
STJ
93
DELISTED
St Jude Medical
STJ
– –
-100
Closed -$6K
TRNX
94
DELISTED
TORNIER N V SHARES (NLD)
TRNX
– –
-15,000
Closed -$282K
NPSP
95
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-400,000
Closed -$12.1M
DRTX
96
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
– –
-188,706
Closed -$2.41M
SLTM
97
DELISTED
SOLTA MED INC (DE)
SLTM
– –
-3,356,391
Closed -$9.9M
1 2 3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Broadfin Capital held 97 positions worth $1.03B, up 36% from $758M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Broadfin Capital deployed $156M of net new capital in Q1 2014, opening 37 new positions and adding to 20 existing holdings. Its largest new stake was Heron Therapeutics: 2,233,173 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lannett Company, Inc., an estimated $25.5M trimmed.

  • Broadfin Capital's largest Q1 2014 buy was Heron Therapeutics: 2,233,173 shares worth $31.1M.
  • Broadfin Capital added most to Emergent Biosolutions in Q1 2014, an estimated $18.5M increase.
  • Broadfin Capital's biggest Q1 2014 reduction was Lannett Company, Inc., cutting an estimated $25.5M.
  • Broadfin Capital fully exited NPS PHARMACEUTICALS INC in Q1 2014, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 40% of its $1.03B portfolio in Q1 2014.
  • Broadfin Capital opened 37 new positions and closed 12 in Q1 2014.
  • Broadfin Capital's portfolio value rose 36% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.